New insights into PDE4B inhibitor selectivity: CoMFA analyses and molecular docking studies

被引：0
|
作者：
Sara Guariento
Olga Bruno
Paola Fossa
Elena Cichero
机构：
[1] University of Genoa,Department of Pharmacy
来源：
Molecular Diversity | 2016年 / 20卷
关键词：
Phosphodiesterases; PDE4B inhibitors; PDE4D; Molecular docking; Selectivity; CoMFA;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：77 / 92
页数：15
相关论文
共 50 条
  • [31] 3D QSAR Studies of 2-Arylpyrimidines and S-Triazines as Selective PDE4B Inhibitors
    Gaurav, Anand
    Kumar, Dharmendra
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2018, 12 (03): : 1303 - 1307
  • [32] Novel quinoline-based derivatives: A new class of PDE4B inhibitors for adjuvant-induced arthritis
    Xing, Siqi
    Fan, Weizheng
    Chen, Junhua
    Du, Jiyu
    Liu, Tongtong
    Dong, Shuanghong
    Xia, Jucheng
    Liu, Peipei
    Zou, Dexing
    Cai, Li
    Li, Zeng
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 238
  • [33] Structural insights into the lead identification of sub-type selective PDE4B inhibitors from plant bioactive molecule analogues
    Sharma, Bhanu
    Purohit, Rituraj
    JOURNAL OF MOLECULAR LIQUIDS, 2023, 390
  • [34] Population Pharmacokinetic-Pharmacodynamic (popPK/PD) Relationship of Orismilast, A Potent and Selective PDE4B/D Inhibitor, in Atopic Dermatitis
    Warren, Richard B.
    Weiss, Anne
    Felding, Jakob
    Sommer, Morten O. A.
    DERMATOLOGY AND THERAPY, 2025, : 831 - 839
  • [35] RNR inhibitor binding studies of Chlamydia felis: insights from in silico molecular modeling, docking, and simulation studies
    Ravindranath, B. S.
    Vinayak, S. Vishnu
    Mohan, Vivek Chandra
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (19): : 9416 - 9428
  • [36] Understanding the structure-activity and structure-selectivity correlation of cyclic guanine derivatives as phosphodiesterase-5 inhibitors by molecular docking, CoMFA and CoMSIA analyses
    Yang, GF
    Lu, HT
    Xiong, Y
    Zhan, CG
    BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (05) : 1462 - 1473
  • [37] Staying in the Flow: Preferential PDE4B Inhibitor Nerandomilast (BI 1015550) Improves Features of Vascular Dysfunction in Lung Fibrosis In Vitro and In Vivo
    Reininger, D.
    Wolf, F.
    Mayr, C. H.
    Nickolaus, P.
    Herrmann, F. E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [38] Molecular docking and molecular dynamics simulation studies of Trypanosoma cruzi triosephosphate isomerase inhibitors. Insights into the inhibition mechanism and selectivity
    Minini, Lucia
    Alvarez, Guzman
    Gonzalez, Mercedes
    Cerecetto, Hugo
    Merlino, Alicia
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2015, 58 : 40 - 49
  • [39] PDE4B Inhibitor CV-1238 Demonstrates Both Anti-Depressant and Anti-Psychotic Properties in Preclinical Models
    Gyoneva, Stefka
    Stolyar, Polina
    Leiser, Steven C.
    Bardehle, Sophia
    Chakilam, Srinivas
    Zhang, Hongjun
    Iredale, Philip
    Suidan, Georgette
    NEUROPSYCHOPHARMACOLOGY, 2023, 48 : 273 - 274
  • [40] BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis (vol 13, 838449, 2022)
    Herrmann, Franziska Elena
    Hesslinger, Christian
    Wollin, Lutz
    Nickolaus, Peter
    FRONTIERS IN PHARMACOLOGY, 2023, 14
12345